Oliver Politz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2525175/publications.pdf

Version: 2024-02-01

1937685 2272923 4 155 4 4 citations h-index g-index papers 4 4 4 354 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models. Blood Advances, 2020, 4, 819-829.	5.2	28
2	Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor. Molecular Cancer Therapeutics, 2020, 19, 1289-1297.	4.1	11
3	Rogaratinib: A potent and selective panâ€FGFR inhibitor with broad antitumor activity in FGFRâ€overexpressing preclinical cancer models. International Journal of Cancer, 2019, 145, 1346-1357.	5.1	65
4	BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signalingâ€dependent tumor growth in mouse models. International Journal of Cancer, 2017, 140, 449-459.	5.1	51